Mitchell Lipton
Cardiovascular Disease · Brooklyn, NYNPI 1093711467
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,694 and has fallen 99.0% since, to $26 in 2023.
Across 251 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$797
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$519
- AstraZeneca$389
- Amarin Pharma, Inc.$373
- Boehringer Ingelheim$355
- Novo Nordisk$318
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,138100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $797 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $519 |
| AstraZeneca | 20 | $389 |
| Amarin Pharma, Inc. | 22 | $373 |
| Boehringer Ingelheim | 17 | $355 |
| Novo Nordisk | 11 | $318 |
| Johnson & Johnson | 17 | $308 |
| Esperion Therapeutics, Inc. | 10 | $267 |
| E.r. Squibb & Sons, L.L.C. | 16 | $243 |
| Lilly USA, LLC | 14 | $215 |
| Kowa Pharmaceuticals America, Inc. | 13 | $200 |
| Arbor Pharmaceuticals, Inc. | 9 | $169 |
| Medtronic | 2 | $169 |
| Pfizer | 9 | $155 |
| Merck | 9 | $155 |
| Regeneron Healthcare Solutions, Inc. | 5 | $125 |
| Sanofi-aventis U.S. LLC | 4 | $80 |
| AbbVie(2 entities) | 5 | $79 |
| Novartis | 3 | $63 |
| Hikma Pharmaceuticals USA | 4 | $61 |
| Boston Scientific | 1 | $26 |
| Astellas Pharma US Inc | 1 | $20 |
| Genentech, Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| GSK | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$248
- CoreValve Evolut$152
- NEXLIZET$143
- NEXLETOL$143
- Ozempic$118
How this compares
$5,138 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$426K
- Warren WexelmanBrooklyn$396K
- Ozgen DoganBrooklyn$290K
- Sergey AyzenbergBrooklyn$157K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.